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Two in every three deaths among women are caused by non-communicable diseases (NCDs)  largely heart
disease, stroke, cancer, diabetes and chronic respiratory diseases. The global discourse on health, however,
largely views women in terms of their reproductive capacity, a persisting myth reflecting gender bias that shifts
the focus away from NCDs, violence, and other injuries. Risk factors for NCDs are similar for men and
women. Because fewer women actively smoke than men, and drink in less harmful ways, in most parts of the
world, the impact of major NCD risk factors is far less in women than in men. In the area of diagnosis and
treatment, gender bias can result in women being asked fewer questions, and receiving fewer examinations
and fewer diagnostic tests for coronary heart disease and other NCDs compared with men with similar
symptoms. In response to a UN meeting in September 2011, member states of WHO have agreed to a global
goal to reduce avoidable NCD mortality by 25% by 2025 (‘25 by 25’). A set of voluntary targets and indictors
have been agreed upon, although none of them are gender specific. Most require changes at the policy level
that will ensure that women  and children  will also benefit. As the 2015 deadline for the Millennium
Development Goals approaches, women and NCDs should be central to the sustainable human development
agenda.
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F
our major transitions are occurring in global
health: age, sex, and cause-specific death rates
are generally declining; life expectancy is increas-
ing; populations are aging; and there is a dramatic shift
from deaths at younger ages, principally due to infectious
diseases, to non-communicable diseases (NCDs)  prin-
cipally cardiovascular diseases (CVDs), cancer, chronic
respiratory diseases, and diabetes. NCDs have been the
leading causes of death among women globally for at
least the past three decades and are now responsible for
two in every three deaths among women each year (1).
Several enduring myths have contributed to the neglect
of NCDs in women (2). First, there is a strong and
persistent view that only health-related issues of impor-
tance to women are defined through their reproductive
capacity (3), yet two thirds of all deaths and disabilities
in women relate to chronic diseases, violence, and other
injuries. This myth in particular, reflects, in part, a gender
bias (4). Second, NCDs, especially CVDs, have been
considered primarily as diseases of men. Although age-
specific NCD death rates in women lag behind the rates in
men by about 10 years, the absolute number of NCD
deaths in women (16.2 million) is similar to that of men
(18.4 million) because women live longer  on average,
between 6 and 8 years (5). The third myth is that NCDs in
women are an issue only in high-income countries. In fact,
most NCD deaths in women occur in low- and middle-
income countries and the rates in these countries aremuch
higher than in wealthy countries. The fourth and the most
distressing myth is that NCDs cause deaths only in older
people and ‘we have to die of something, so why bother
with complicated conditions like NCDs’. Unfortunately,
and especially now in low- and middle-income countries,
NCD deaths are frequent in people under the age of 70
years, including women, and many of these deaths are
slow and miserable. A large proportion of NCD deaths,
especially before old age, are avoidable with cheap, cost-
effective, and in some cases, cost-saving interventions.
The good news is that, despite the overall increasing
number of NCD deaths in women due to increasing
population size and aging, the age-specific death rates,
especially for CVD, are declining, and in some countries,
surprisingly quickly (68). In many countries, the decline
began before governments or non-governmental organi-
zations mounted awareness and prevention campaigns.
It is likely that the initial decline in death rates was due to
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gical studies, notably the Framingham Heart Study, and
the powerful evidence on the relationship between
tobacco use, lung cancer, and CVD that began to be
disseminated in the 1960s.
More recently, treatments  especially drugs to manage
high levels of blood pressure and cholesterol  have also
playedanimportantpartincontinuingthedeclineindeath
rates which now include lung cancer in men, but not yet
women, as well as stomach, breast, and cervical cancers.
The challenge now is to apply globally the interventions
that have been so beneficial to women in high-income
countries.
Riskfactorsforheartdiseaseandstroke,thetwoleading
causes of death among women, are similar for men and
women. Factors such as age and family history play a role,
but the majorityof CVD deaths are due to modifiable risk
factors such as tobacco use; diets high in fat, salt, and
sugar; high blood pressure; high cholesterol; obesity; and
diabetes. Because fewer women actively smoke  or have
smoked for a shorter time  than men, and because they
drink less and in less harmful ways than do men, in most
partsoftheworldthemajorNCDriskfactorscauselessof
a burden in women than in men (9) and therefore more
ambitious risk factor targets will be required for women
than for men to achieve the ‘25 by 25’ premature NCD
mortalitytargetsetbyWHO(10).Dietaryriskfactorshave
broadly similar effects for both women and men. With the
exceptionofhighbodymassindexandhighfastingplasma
glucose, most of the leading risk factors for NCDs have
declined, especially in high-income countries (3). Obesity
levelsareaconcernforwomen;almosteverywhere,women
are more obese than men. There are also significant
differences in the way both symptomatic and asympto-
matic women are treated compared to men. For example,
gender, but not age, race, or social class of a patient
significantly influenced doctors’ diagnostic and manage-
mentactivitiesinastudythatcontrolledforthesevariables
simultaneously. Women were asked fewer questions, re-
ceived fewer examinations, and had fewer diagnostic tests
ordered for coronary heart disease (11, 12). These differ-
ences are a reflection of the strong gender bias against
equitable prevention and treatment of women (13).
The future of women and the treatment of NCDs is
encouraging. There is an increasing recognition of the
importance of a life course approach to the prevention of
NCDs beginning with the health of girls and young
women before and during pregnancy (14). The integration
of NCD prevention activities into maternal and women-
centric health programs has considerable potential since
there is generally poor access to care for women, girls, and
other vulnerable groups affected by NCDs (15). In many
societies, women lack control over resources and, hence,
cannot afford quality care for NCDs. Women also face
sociocultural, geographic, andeconomic barrierstoaccess
to care. They are less recognized and catered to in terms of
accessibility, comprehensiveness, and responsiveness of
healthcare systems.
Furthermore, there have been major global initiatives
to overcome the general neglect of NCDs. The UN High-
Level Meeting on the Prevention and Control of NCDs
in September 2011 was a turning point. Heads of state
and governments made many major commitments to
reverse the neglect of NCDs, and the health of women
figures prominently in the political declaration from this
meeting (16). In response to the UN meeting, member
states of WHO have agreed upon a global goal to reduce
avoidable NCD mortality by 25% by 2025 (‘25 by 25’),
and a set of voluntary targets and indictors have also
been agreed upon, although none of them are gender
specific (17).
The targets agreed upon by WHO member states cover
nine areas. The Lancet NCD Action Group has proposed
a smaller set of priority targets  three to five  in the
belief that it is important for countries, especially those
beginning their prevention and management efforts, to
concentrate on interventions which are among the ‘best
buys’ in terms of health impact and will thus ensure rapid
progress toward the ‘25 by 25’ goal (18). Of course, once
experience and capacity builds, a broader range of
interventions should be implemented. The Lancet NCD
Action Group proposes a stepwise approach to NCD
prevention beginning with sustained high-level leader-
ship; multisectoral action; a focus on tobacco control and
salt reduction; and the identification in primary health
care of women and men at high overall risk of CVD
( 30% over 10 years) and their treatment with cheap
generic combination drugs (19).
Tobacco control is an excellent entry point for NCD
prevention,andacceleratedimplementationoftheFrame-
work Convention on Tobacco Control is top priority.
Tobacco use in high-income countries is at comparable
levels among women and men, and in most of these
countries, the prevalence of smoking is declining slowly as
an increasing range of evidence-based cost-saving control
measuresareintroduced.Themosteffectiveinterventionis
regular and substantial increases in the price of tobacco;
plain packaging of tobacco products, first introduced in
Australia in 2012, has opened a new phase in the fight
against the tobacco industry.
Fortunately, in many low- and middle-income coun-
tries, for example, China and Indonesia, smoking rates
are substantially lower in women than in men. This
market represents a major opportunity for the tobacco
industry, and it is doing its best to recruit new smokers,
including enticing young women. Women use tobacco in
a variety of forms, not just smoked tobacco. For this
reason, the proposed WHO voluntary target is to reduce
tobacco use by 30% by 2025. This target is not sufficiently
ambitious and, following the lead of New Zealand which
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(that is, a smoking prevalence of B5%), the Lancet NCD
Action Group is proposing a tobacco-free world by 2040
(20). Secondhand smoke is a particular issue for women
in low- and middle-income countries that do not yet have
effective smoke-free environments (21). Effective legisla-
tion to protect people, especially women and children,
from secondhand smoke is a priority.
Salt reduction will have an important effect on reducing
population blood pressure levels through its impact on
CVDs (22). Although the dominant approach in wealthy
countries to lowering blood pressure is through medical
treatment, this approach is not practical or affordable in
most countries (23). Because about half the CVD events
occur in people with ‘normal’ blood pressures, that is,
below a systolic blood pressure of 140 mmHg, population
salt reduction has the major advantage of leading to fewer
CVD deaths in these people. Women will play a vital role
in cultures where salt is overused; they can more easily
take a leadership role at the household level in terms of
reducing discretionary salt use. The agreed upon volun-
tary target is a 30% reduction in per capita salt intake by
2025; the original WHO target was a per capita intake of
5 g per day (24).
The priority treatment goal is to increase the coverage
in primary health care of generic drugs for men and
women at high risk of CVD. The dominant approach to
the medical management of high risk is to treat individual
elevated risk factors based on arbitrary cut points for
‘abnormality’. A much more efficient approach is to
manage people at elevated overall risk based on their age,
gender, and combined risk factor status; this approach
will lead to a lower number of women on treatment 
because of their lower overall risk  and better use of
limited resources for the same or greater health impact.
However, for this approach to reach its potential, it will
need to be embraced by health professionals trained in
the traditional medical model.
Assuring progress toward the NCD goal ‘25 by 25’,
requires the establishment of an independent account-
ability mechanism, monitoring trends, reviewing pro-
gress, and acting as indicated to accelerate progress
(25). A useful precedent has been set by the establishment
of an independent expert advisory group to oversee
progress toward the goals for Women’s and Children’s
health; this model has relevance to NCDs. It is desirable
for NCDs to be incorporated into the accountability
mechanisms for other global health priorities.
As the 2015 deadline for the Millennium Development
Goals approaches, discussions are underway on the post-
2015 development agenda. It is critical that women and
NCDs are central to the new human development
agenda. So far, the prospects are promising with NCDs
being recognized in the health consultations as being
central to human development. If NCDs assume their
rightful place post-2015, women throughout the world
will benefit enormously.
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